We are live on ! Find out more
FI

Fosun International Portfolio holdings

AUM $399M
1-Year Est. Return 16.11%
This Fund
S&P 500
This Quarter Est. Return
-8.62%
1 Year Est. Return
-16.11%
3 Year Est. Return
+16.92%
5 Year Est. Return
-0.68%
10 Year Est. Return
+98.52%
AUM
$902M
AUM Growth
-$613M
Cap. Flow
-$411M
Cap. Flow %
-45.55%
Top 10 Hldgs %
57.67%
Holding
342
New
42
Increased
40
Reduced
54
Closed
115

Top Buys

Rank Stock Value
1
AMRX icon
Amneal Pharmaceuticals
AMRX
+$6.87M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$3.2M
3
TSM icon
TSMC
TSM
+$1.88M
4
BKNG icon
Booking.com
BKNG
+$1.49M
5
WPM icon
Wheaton Precious Metals
WPM
+$1.48M

Top Sells

Rank Stock Value
1
DBRG icon
DigitalBridge
DBRG
+$33.8M
2
ARRY
Array Biopharma Inc
ARRY
+$23.1M
3
INCY icon
Incyte
INCY
+$10.1M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$9.75M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$9.33M

Sector Composition

Rank Sector Weight
1 Healthcare 16.66%
2 Industrials 5.91%
3 Financials 5.49%
4 Technology 5.04%
5 Communication Services 3.56%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MSCI icon
251
MSCI
MSCI
$41.9B
– –
-875
Closed -$205K
NBIX icon
252
Neurocrine Biosciences
NBIX
$18.7B
– –
-118,323
Closed -$9.75M
NOW icon
253
ServiceNow
NOW
$114B
– –
-3,750
Closed -$209K
NXTC icon
254
NextCure
NXTC
$20.5M
– –
-12,500
Closed -$2.25M
OMCL icon
255
Omnicell
OMCL
$1.69B
– –
-11,000
Closed -$949K
OPK icon
256
Opko Health
OPK
$993M
– –
-858,142
Closed -$1.91M
ORCL icon
257
Oracle
ORCL
$367B
– –
-14,655
Closed -$832K
PLX icon
258
Protalix BioTherapeutics
PLX
$183M
– –
-263,140
Closed -$1.24M
PRTA icon
259
Prothena Corp
PRTA
$440M
– –
-110,179
Closed -$1.11M
PTGX icon
260
Protagonist Therapeutics
PTGX
$8.92B
– –
-47,513
Closed -$569K
RARE icon
261
Ultragenyx Pharmaceutical
RARE
$2.56B
– –
-54,144
Closed -$3.36M
RNAC icon
262
Cartesian Therapeutics
RNAC
$227M
– –
-14,611
Closed -$824K
RYTM icon
263
Rhythm Pharmaceuticals
RYTM
$7.25B
– –
-40,720
Closed -$883K
SGMO
264
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
– –
-62,808
Closed -$663K
SLNO
265
DELISTED
Soleno Therapeutics
SLNO
– –
-12,599
Closed -$514K
SPRO icon
266
Spero Therapeutics
SPRO
$69.5M
– –
-86,596
Closed -$962K
STZ icon
267
Constellation Brands
STZ
$22.3B
– –
-1,960
Closed -$369K
SYBX
268
DELISTED
Synlogic
SYBX
– –
-2,563
Closed -$342K
SYRE icon
269
Spyre Therapeutics
SYRE
$8.81B
– –
-8,166
Closed -$1.31M
TBPH icon
270
Theravance Biopharma
TBPH
$873M
– –
-185,899
Closed -$2.97M
TVTX icon
271
Travere Therapeutics
TVTX
$5.33B
– –
-56,837
Closed -$1.14M
VKTX icon
272
Viking Therapeutics
VKTX
$3.84B
– –
-69,203
Closed -$579K
WVE icon
273
Wave Life Sciences
WVE
$1.11B
– –
-70,088
Closed -$1.84M
XOMA
274
DELISTED
Xoma
XOMA
– –
-266,877
Closed -$3.94M
XOM icon
275
ExxonMobil
XOM
$651B
– –
-16,150
Closed -$1.22M
9 10
11
12 13

Similar funds

NC
NovaPoint Capital Atlanta, Georgia $399M AUM 26.97% 1-Year Est. Return
T2I
Turim 21 Investimentos Rio De Janeiro, Brazil $399M AUM 20.13% 1-Year Est. Return
BA
Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return
IAA
Ironsides Asset Advisors Rocky Mount, North Carolina $399M AUM 13.99% 1-Year Est. Return
THL
Tillman Hartley LLC Denver, Colorado $398M AUM 16.44% 1-Year Est. Return
MHC
May Hill Capital Cohasset, Massachusetts $398M AUM 23.9% 1-Year Est. Return
BWM
BCGM Wealth Management Lafayette, Indiana $398M AUM 17.85% 1-Year Est. Return
KHCM
Kettle Hill Capital Management New York $399M AUM 10.05% 1-Year Est. Return

Fosun International's Q3 2019 Portfolio in Review

As of Q3 2019, Fosun International held 342 positions worth $902M, down 40% from $1.51B the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Fosun International withdrew a net $411M in Q3 2019, closing 115 positions and reducing 54 holdings. Its most notable exit was DigitalBridge, an estimated $33.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 17% of assets, down from 32% a quarter earlier, followed by Industrials and Financials.

Against the trend, Fosun International opened a new position in Zoetis worth $1.24M.

  • Fosun International's largest Q3 2019 buy was Zoetis: 10,000 shares worth $1.24M.
  • Fosun International added most to Amneal Pharmaceuticals in Q3 2019, an estimated $6.87M increase.
  • Fosun International's biggest Q3 2019 reduction was BioMarin Pharmaceuticals, cutting an estimated $7.14M.
  • Fosun International fully exited DigitalBridge in Q3 2019, selling an estimated $33.8M.
  • Fosun International's ten largest holdings make up 58% of its $902M portfolio in Q3 2019.
  • Fosun International opened 42 new positions and closed 115 in Q3 2019.
  • Fosun International's portfolio value fell 40% quarter-over-quarter to $902M.

Based on Fosun International's 13F filing for Q3 2019, filed 12 Nov 2019.